Despite sound science, many recent drug launches are failing. The root cause is not the data but an underinvestment in market conditioning. Cautious investors and tighter budgets mean companies are starting their educational and scientific storytelling efforts too late, failing to prepare the market adequately.

Instead of waiting 90 days for functional outcomes, Revolicio's Phase 2 trial used MRI scans at 0 and 48 hours to measure brain tissue loss. This provided a direct, early biomarker of the drug's physiological effect, which correlated strongly with later clinical benefits and de-risked the subsequent Phase 3 trial.

In the difficult CNS space, novel drugs often fail because of an inability to prove target engagement in humans. By choosing metabolic targets, Leal can use clear biomarkers from blood tests or imaging to de-risk its programs and provide early proof of efficacy to investors, clinicians, and partners.

To secure investment in the high-risk neurodegeneration space, companies must avoid significant 'leaps of faith.' A key de-risking factor is applying novel modalities to clinically validated pathways. This provides a stronger scientific foundation than pursuing a completely unproven biological hypothesis, making the venture more compelling to investors.

In today's tightened market, a brilliant scientific platform isn't enough to secure investment. Investors have shifted to a product-focused lens, requiring founders to present a clear, detailed pathway from their idea to an approved drug. This includes defining the unmet medical need and outlining the proposed clinical trial design from day one.

The FDA's refusal to approve a promising Huntington's drug, despite strong biological evidence, has a chilling effect on the entire biotech ecosystem. Other drug companies become nervous, and venture capital funding for neurological and rare disease research is likely to retract without a clear path to market.

While scientifically exciting, pioneering a new biological pathway makes investors more conservative, as there is no proven path to follow. K-36's CEO notes this paradox: it requires more effort to educate investors and define a new space compared to a 'fast-follower' company with a clearer, pre-validated market.

The core technology behind RNS60 was first used to deliver oxygenated nutrients to plant roots, which increased crop yields and stress resistance. The founder's insight was to question if a similar protective effect could be replicated in human biology, demonstrating a powerful case of cross-domain innovation from agriculture to medicine.

Abivax's stock plummeted despite best-in-class efficacy for its ulcerative colitis drug. Investors fixated on a few cancer cases deemed unrelated to the treatment, showing extreme risk aversion to new biological pathways where long-term safety is uncertain.